Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,408 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Volunteers Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Top-Down Attentional Control of Visual-Processing

NCT01087281
View directory record Official record
Conditions
Focal Brain Lesion, Focal Lesions, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 6:03 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

NCT06411730
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986368
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

NCT04510675
View directory record Official record
Conditions
Erythema, Sensitisation
Interventions
Test Article, Negative Control
Device · Other
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use

NCT01204866
View directory record Official record
Conditions
Allergic Reactions
Interventions
Valortim and selected Components, Valortim and Selected Components
Biological · Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2010 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

NCT01739647
View directory record Official record
Conditions
Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions
AZD3293, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02073227
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fat Induced Insulin Resistance and Atherosclerosis

NCT02348190
View directory record Official record
Conditions
Other Fatty Acid Oxidation Disorders, Diabetes Mellitus, Insulin Resistance
Interventions
Lipid/heparin
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

NCT03300570
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Dolcanatide, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

NCT04009824
View directory record Official record
Conditions
Mosquito-Borne Infectious Diseases
Interventions
AGS-v PLUS Vaccine, Montanide ISA-51 Adjuvant, Alhydrogel® Adjuvant, Saline Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Paleolithic Diet and Exercise Study

NCT00360516
View directory record Official record
Conditions
Diet
Interventions
metabolic (nutrient controlled) diet
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota

NCT01473368
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Saccharomyces boulardii, Amoxicillin Clavulanate
Dietary Supplement · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

NCT05717686
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
AHB-137 injection, Placebo
Drug
Lead sponsor
AusperBio Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Redwood City, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 26, 2026, 6:03 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Neuroimaging Study

NCT03618186
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Tau PET scan
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aldena STAR Particles

NCT06004973
View directory record Official record
Conditions
Healthy
Interventions
STAR Particles, Gel without STAR Particles
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 26, 2026, 6:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

NCT02047656
View directory record Official record
Conditions
Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions
LFF269, Placebo to LFF269
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 26, 2026, 6:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT05859724
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NM26-2198, Placebo
Biological · Other
Lead sponsor
Yellow Jersey Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fountain Valley, California • Glendale, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of AG-348 in Healthy Volunteers

NCT02149966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AG-348, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers

NCT01132703
View directory record Official record
Conditions
Traumatic Brain Injury, Stroke
Interventions
Glyburide for Injection, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

NCT00822341
View directory record Official record
Conditions
Healthy
Interventions
TG-0054
Drug
Lead sponsor
GPCR Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

NCT02751294
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 26, 2026, 6:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Isoflurane at Subanesthetic Concentrations - 6

NCT00000254
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
40% Nitrous oxide, Sham comparator, 0.2% isoflurane, 0.4% isoflurane, 0.6% isoflurane
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 34 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 26, 2026, 6:03 PM EDT